Cited by 177Drug-Induced Hepatotoxicity and ProtectionPharmacovigilance and Adverse Drug ReactionsThyroid Disorders and Treatments

Dissimilar Hepatotoxicity Profiles of Propylthiouracil and Methimazole in Children

Rivkees, Scott A., Szarfman, Ana·2010·The Journal of Clinical Endocrinology & Metabolism

Abstract

BACKGROUND: The antithyroid drugs propylthiouracil and methimazole were introduced for clinical use about 60 yr ago and are estimated to be used in more than 6000 children and adolescents per year in the United States. Over the years that these medications have been used, reports of adverse events involving hepatotoxicity have appeared. To date, there has not been a systematic and comparative evaluation of the adverse events associated with antithyroid drug use. OBJECTIVE: Our objective was to assess safety and hepatotoxicity profiles of propylthiouracil and methimazole by age in the U.S. Food and Drug Administration's Adverse Event Reporting System (AERS). DESIGN: We used the multi-item gamma-Poisson shrinker (MGPS) data mining algorithm to analyze more than 40 yr of safety data in AERS. MGPS uses a Bayesian model to calculate adjusted observed to expected ratios [empiric Bayes geometric mean (EBGM) values] for every drug-adverse event combination in AERS, focusing on hepatotoxicity events. RESULTS: MGPS identified higher-than-expected reporting of severe liver injury in pediatric patients treated with propylthiouracil but not with methimazole. Propylthiouracil had a high adjusted reporting ratio for severe liver injury (EBGM 17; 90% confidence interval = 11.5-24.1) in the group less than 17 yr old. The highest EBGM values for methimazole were with mild liver injury in the group 61 yr and older [EBGM 4.8 (3.3-6.8)], which consisted of cholestasis. Vasculitis was also observed for propylthiouracil in children and adolescents, reaching higher EBGM values than hepatotoxicity signals. CONCLUSIONS: MGPS detects higher-than-expected reporting of severe hepatotoxicity and vasculitis in children and adolescents with propylthiouracil but not with methimazole.

Integrity signals

Registry

Crossref · 10.1210/jc.2009-2546

Cites

33 of 33 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Rivkees, S. A., & Szarfman, A.
Affiliations
  • Yale University (US)
  • United States Food and Drug Administration (US)
Corresponding author
Rivkees, Scott A.
Venue
The Journal of Clinical Endocrinology & Metabolism
Published
2010-07-01
Volume
95
Issue
7
Pages
3260-3267
ISSN
  • 0021-972X (ISSN-L)
  • 1945-7197
OpenAlex
W2061857583
Cited by
177
References
33
Citations by year
2026: 9 · 2025: 21 · 2024: 4 · 2023: 4 · 2022: 3 · 2021: 5 · 2020: 9 · 2019: 10 · 2018: 13 · 2017: 10 · 2016: 15 · 2015: 18 · 2014: 16 · 2013: 10 · 2012: 9
FWCI
12.57
Type
journal article
Language
en
Open access
closed
Locations
  • The Journal of Clinical Endocrinology & Metabolism (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmacology › Drug-Induced Hepatotoxicity and Protection
  • Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Toxicology › Pharmacovigilance and Adverse Drug Reactions
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Thyroid Disorders and Treatments
Keywords
propylthiouracil, methimazole, antithyroid drugs, hepatotoxicity, drug-induced liver injury, drug safety in children, adverse drug reactions, vasculitis, cholestasis, FDA Adverse Event Reporting System, multi-item gamma Poisson shrinker
MeSH terms
Adolescent, Age Factors, Algorithms, Child, Female, Humans, Male, Methimazole, Propylthiouracil, Severity of Illness Index, Antithyroid Agents, United States, United States Food and Drug Administration, Databases, Factual, Adverse Drug Reaction Reporting Systems, Chemical and Drug Induced Liver Injury, Data Mining

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review